PIRS vs. EDSA, MIRA, KPRX, PPBT, FLGC, VINC, RDHL, HUGE, OGEN, and IMNN
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include Edesa Biotech (EDSA), MIRA Pharmaceuticals (MIRA), Kiora Pharmaceuticals (KPRX), Purple Biotech (PPBT), Flora Growth (FLGC), Vincerx Pharma (VINC), RedHill Biopharma (RDHL), FSD Pharma (HUGE), Oragenics (OGEN), and Imunon (IMNN). These companies are all part of the "pharmaceutical preparations" industry.
Edesa Biotech (NASDAQ:EDSA) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking.
In the previous week, Edesa Biotech and Edesa Biotech both had 4 articles in the media. Edesa Biotech's average media sentiment score of 1.25 beat Pieris Pharmaceuticals' score of 0.97 indicating that Pieris Pharmaceuticals is being referred to more favorably in the news media.
Edesa Biotech presently has a consensus target price of $39.00, suggesting a potential upside of 816.29%. Given Pieris Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Edesa Biotech is more favorable than Pieris Pharmaceuticals.
Edesa Biotech has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. 25.0% of Edesa Biotech shares are held by insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Pieris Pharmaceuticals received 253 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 75.76% of users gave Edesa Biotech an outperform vote while only 61.37% of users gave Pieris Pharmaceuticals an outperform vote.
Edesa Biotech has higher earnings, but lower revenue than Pieris Pharmaceuticals.
Edesa Biotech has a net margin of 0.00% compared to Edesa Biotech's net margin of -39.71%. Edesa Biotech's return on equity of -57.57% beat Pieris Pharmaceuticals' return on equity.
Summary
Edesa Biotech and Pieris Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
